Although much more rare than its diabetic counterpart, ketoacidosis secondary to alcohol withdrawal in the context of fasting has its own complex pathophysiology and can easily mimic the acute insulin deficiency presentation. We present here a rare case of a non-diabetic alcoholic patient who presented in ketoacidosis after a period of reduced intake.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087634 | PMC |
http://dx.doi.org/10.14740/jocmr2751w | DOI Listing |
J Health Popul Nutr
November 2024
Department of Population, Family, Reproductive Health, School of Public Health, University of Ghana, Accra, Ghana.
Background: Few studies have reported hyperglycemia and diabetic ketoacidosis in patients on dolutegravir (DTG) treatment. This study determined the effect of DTG on fasting blood glucose levels in a cohort of persons living with HIV (PLHIV) in Ghana and initiating DTG regimens.
Methods: A two-year observational longitudinal cohort study conducted from 12th October 2020 to 31st December 2022.
J Gen Intern Med
October 2024
WellSpan Hospital, York, PA, USA.
Euglycemic ketoacidosis is an acute, life-threatening emergency that is characterized by euglycemia, metabolic acidosis, and ketonemia. It is a well-recognized adverse event in diabetic patients taking sodium-glucose cotransporter-2 inhibitor (SGLT-2 inhibitor). However, there is limited data on SGLT-2 inhibitor-related euglycemic ketoacidosis in non-diabetic patients.
View Article and Find Full Text PDFBMC Pediatr
September 2024
Department of Pediatrics, Peking Union Medical College Hospital (PUMCH), Beijing, 100730, China.
J Pharm Pract
February 2025
Department of Pharmacy, St. Joseph's/Candler Health System, Savannah, GA, USA.
Sodium-glucose transporter-2 inhibitors (SGLT2i) are commonly used for the treatment of Type 2 Diabetes Mellitus, offering additional benefits in non-diabetic patients with conditions such as chronic kidney disease and heart failure. However, SGLT2i have been associated with an increased risk of euglycemic diabetic ketoacidosis (DKA). This case series describes three cases of patients who developed euglycemic DKA while taking SGLT2i.
View Article and Find Full Text PDFJ Diabetes Metab Disord
June 2024
Pediatric Intensive Care Unit, CHU de Caen, F-14000 Caen, France.
This case report presents a 9-year-old child without underlying pathology, with a severe life-threatening non-diabetic metabolic ketoacidosis occurring less than 48 h after the onset of fasting and vomiting. The patient was admitted to the pediatric intensive care unit. He received volume expansion and maintenance fluid therapy which allowed a favorable evolution.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!